Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis Delta

Benzinga Newsdesk www.benzinga.com Neutral 80.3%

Neg 0% Neu 80.3% Pos 0%

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026.